Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Haus

Internal Medicine Mansfield, OH Doctor of Osteopathy

NPI 1114128311 CMS profile 277464

2293 Village Park Ct, Mansfield, OH 44906

Open in the dashboard

General payments

$15,955

1,099 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Haus of Mansfield, OH is reported in the CMS Open Payments database as having received $15,955 across 1,099 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,063 186
2024 General $2,976 177
2023 General $2,438 170
2022 General $2,264 161
2021 General $1,602 123
2020 General $1,634 133
2019 General $1,978 149

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Haus
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Eric Haus were reported at $3,063. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Eric Haus Internal Medicine median Middle half National median
2019 $1,978 $159 $48–$570 $163
2020 $1,634 $119 $33–$402 $114
2021 $1,602 $135 $37–$521 $132
2022 $2,264 $141 $42–$496 $149
2023 $2,438 $149 $45–$519 $160
2024 $2,976 $154 $47–$537 $164
2025 $3,063 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,370 173 payments
  2. AstraZeneca Pharmaceuticals LP $1,894 93 payments
  3. Novo Nordisk Inc $1,516 122 payments
  4. Pfizer Inc. $1,272 117 payments
  5. GlaxoSmithKline, LLC. $963 83 payments
  6. Novartis Pharmaceuticals Corporation $831 49 payments
  7. Lilly USA, LLC $815 61 payments
  8. Amgen Inc. $806 55 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $365 24 payments
  10. Janssen Pharmaceuticals, Inc $340 19 payments
  11. Other $4,782 303 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,928 1,095 payments
  2. Education $27 4 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $1,370 100 payments
  2. Ozempic $1,067 87 payments
  3. QULIPTA $851 71 payments
  4. BREZTRI $815 33 payments
  5. FARXIGA $761 31 payments
  6. LEQVIO $711 41 payments
  7. TRELEGY ELLIPTA $668 55 payments
  8. NURTEC ODT $668 57 payments
  9. RYBELSUS $646 54 payments
  10. LINZESS $546 34 payments
  11. Other $13,648 950 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 164 drugs

Part D claims

13,381

Median for Internal Medicine: 777

Drug cost

$1,205,832

Median for Internal Medicine: $73,373

Branded share of claims

25%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 186 $178,713
Ozempic Semaglutide Brand 127 $167,273
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 142 $129,201
Xarelto Rivaroxaban Brand 50 $70,444
Jardiance Empagliflozin Brand 58 $68,416
Entresto Sacubitril/Valsartan Brand 53 $66,678
Mounjaro Tirzepatide Brand 37 $63,814
Farxiga Dapagliflozin Propanediol Brand 67 $54,541
Prolia Denosumab Brand 19 $33,171
Trulicity Dulaglutide Brand 19 $28,098

The 10 drugs with the highest cost, of 164 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$997

Medicare's payments for the services billed

Medicare patients

13

Average age 74

Services billed

33

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 41 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
$369 — —
BREZTRI
$256 21 —
LEQVIO
$240 — —
QULIPTA
$202 — —
VOQUEZNA
$195 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 41 with Patron

Records

1,099 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record